ECSP056104A - Compuestos heterociclicos inmunomoduladores - Google Patents

Compuestos heterociclicos inmunomoduladores

Info

Publication number
ECSP056104A
ECSP056104A EC2005006104A ECSP056104A ECSP056104A EC SP056104 A ECSP056104 A EC SP056104A EC 2005006104 A EC2005006104 A EC 2005006104A EC SP056104 A ECSP056104 A EC SP056104A EC SP056104 A ECSP056104 A EC SP056104A
Authority
EC
Ecuador
Prior art keywords
immunomodulating
heterociclical
compounds
heterociclical compounds
solvate
Prior art date
Application number
EC2005006104A
Other languages
English (en)
Inventor
Ian Richard Mathews
Original Assignee
Avidex Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0305876A external-priority patent/GB0305876D0/en
Priority claimed from GB0319429A external-priority patent/GB0319429D0/en
Application filed by Avidex Ltd filed Critical Avidex Ltd
Publication of ECSP056104A publication Critical patent/ECSP056104A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Surgery (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Los compuestos de la fórmula (I) son inhibidores de CD80 y son útiles en la terapia de inmunomodulación: en donde R1 y R3 representan independientemente H; F; Cl; Br; -NO2; -CN; alquilo de 1 a 6 átomos de carbono sustituido opcionalmente por F o Cl; o alcoxi de 1 a 6 átomos de carbono sustituido opcionalmente por F; R4 representa un grupo de ácido carboxílico (-COOH) o un éster del mismo, o -C(=O)NR6R7, -NR7C(=O)R6, -NR7C(=O)OR6, -NHC(=O)NR7R6 o -NHC(=S)NR7R6, en donde R6 representa H, o un radical de la fórmula -(Alq)m-Q en donde m es 0 o 1, Alq es un radical de alquileno de 1 a 12 átomos de carbono o alquenileno de 2 a 12 átomos de carbono o alquinileno de 2 a 12 átomos de carbono de cadena recta o ramificada, divalente, sustituido opcionalmente o un radical carbocíclico de 3 a 12 átomos de carbono, divalente, cualquiera de estos radicales puede contener una o más uniones de -O-, -S- o -N(R8)-, en donde R8 representa H o alquilo de 1 a 4 átomos de carbono, alquenilo de 3 a 4 átomos de carbono, alquinilo de 3 a 4 átomos de carbono o cicloalquilo de 3 a 6 átomos de carbono y Q representa H; -NR9R10, en donde R9 y R10 representan independientemente H; alquilo de 1 a 4 átomos de carbono; alquenilo de 3 a 4 átomos de carbono; alquinilo de 3 a 4 átomos de carbono; cicloalquilo de 3 a 6 átomos de carbono; un grupo éster; un grupo carbocíclico o heterocíclico sustituido opcionalmente; o R9 y R10 forman un anillo cuando se toman junto con el átomo de nitrógeno al cual están unidos, anillo que es sustituido opcionalmente; y R7 representa H o alquilo de 1 a 6 átomos de carbono; o cuando se toma junto con el átomo o átomos a los cuales están unidos R6 y R7 forman un anillo heterocíclico, monocíclico, sustituido opcionalmente que tiene 5, 6 o 7 átomos del anillo; y X representa un enlace o un radical divalente de la fórmula -(Z)n-(Alq)- o -(Alq)-(Z)n- en donde Z representa -O-, -S- o -NH-, Alq es como se define con relación a R6 y n es 0 o 1.
EC2005006104A 2003-03-14 2005-10-14 Compuestos heterociclicos inmunomoduladores ECSP056104A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0305876A GB0305876D0 (en) 2003-03-14 2003-03-14 Immuno inhibitory heterocyclic compounds
GB0319429A GB0319429D0 (en) 2003-08-19 2003-08-19 Immuno Inhibitory Heterocyclic compounds

Publications (1)

Publication Number Publication Date
ECSP056104A true ECSP056104A (es) 2006-03-01

Family

ID=32992598

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005006104A ECSP056104A (es) 2003-03-14 2005-10-14 Compuestos heterociclicos inmunomoduladores

Country Status (20)

Country Link
US (3) US7276505B2 (es)
EP (2) EP2284172A1 (es)
JP (1) JP4892338B2 (es)
KR (1) KR101133959B1 (es)
AT (1) ATE489388T1 (es)
BR (1) BRPI0408365B8 (es)
CA (1) CA2519063C (es)
DE (1) DE602004030225D1 (es)
DK (1) DK1603917T3 (es)
EA (2) EA014080B1 (es)
EC (1) ECSP056104A (es)
HK (1) HK1090921A1 (es)
IL (1) IL170389A (es)
MX (1) MXPA05009667A (es)
NO (1) NO332136B1 (es)
NZ (1) NZ541973A (es)
PL (2) PL383655A1 (es)
PT (1) PT1603917E (es)
SI (1) SI1603917T1 (es)
WO (1) WO2004081011A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2284172A1 (en) * 2003-03-14 2011-02-16 MediGene Ltd. Immunomodulating heterocyclic compounds
GB0325644D0 (en) * 2003-11-04 2003-12-10 Avidex Ltd Immuno ihibitory pyrazolone compounds
GB0411770D0 (en) * 2004-05-26 2004-06-30 Avidex Ltd Immuno inhibitory heterocyclic compouds
DK1776366T3 (da) * 2004-08-09 2009-02-16 Medigene Ltd Immunomodulerende oxopyrazolocinnoliner som CD80-inhibitorer
WO2007017289A2 (en) * 2005-08-10 2007-02-15 Bayer Schering Pharma Aktiengesellschaft Acyltryptophanols for fertility control
GB0603522D0 (en) * 2006-02-22 2006-04-05 Avidex Ltd Kinase inhibition
AU2007227681A1 (en) 2006-03-15 2007-09-27 Wyeth N-substituted-azacyclylamines as histamine-3 antagonists
CN101432261A (zh) 2006-05-19 2009-05-13 惠氏公司 作为组织胺-3拮抗剂的n-苯甲酰基-吡咯烷-3-基胺和n-苄基-吡咯烷-3-基胺
EP2047848A4 (en) * 2006-07-05 2010-06-09 Univ Tokyo METHOD FOR THE TREATMENT OF GENETIC DISEASES BASED ON A NONSENSE MUTATION
PE20081152A1 (es) 2006-10-06 2008-08-10 Wyeth Corp Azaciclilaminas n-sustituidas como antagonistas de histamina-3
AR067549A1 (es) 2007-07-16 2009-10-14 Wyeth Corp Compuesto de oxazol,tiazol e imidazol, composicion farmaceutica que lo comprende , proceso para la preparacion del compuesto , uso del compuesto y metodos para la inhibicion del receptor h3 y para el tratamiento de un trastorno cognitivo relacionado con o afectado por el receptor de histamina -3 (h3
EP2020404A1 (en) * 2007-08-01 2009-02-04 Bayer Schering Pharma Aktiengesellschaft Cyanomethyl substituted N-Acyl Tryptamines
MX2010003155A (es) 2007-10-04 2010-04-01 Hoffmann La Roche Derivados de ciclopropil aril amida y uso de los mismos.
GB201021104D0 (en) 2010-12-13 2011-01-26 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
EP2676666A1 (en) 2012-06-20 2013-12-25 Eidgenössische Technische Hochschule Zürich (ETH) Compounds for use in diagnosis or therapy of vulnerable atherosclerotic plaques
EP2883883A1 (en) 2013-12-16 2015-06-17 Cardio3 Biosciences S.A. Therapeutic targets and agents useful in treating ischemia reperfusion injury
AU2015315177A1 (en) * 2014-09-10 2017-03-16 Epizyme, Inc. Substituted pyrrolidine carboxamide compounds
WO2018110669A1 (en) 2016-12-15 2018-06-21 Ono Pharmaceutical Co., Ltd. Activator of trek (twik related k+ channels) channels

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB629412A (en) 1946-12-24 1949-09-20 Geigy Ag J R Manufacture of metallisable monoazo dyestuffs of the pyrazolone series
US3576637A (en) * 1967-04-20 1971-04-27 Konishiroku Photo Ind Lith-type of emulsion containing pyrozolone
JPS61161285A (ja) * 1984-12-28 1986-07-21 ルセル−ユクラフ ピラゾロ〔４，３−ｃ〕シンノリン−３−オンの誘導体、それらの塩類、これらの製造法、薬剤としての使用、これらを含有する組成物及び中間体生成物
US4591589A (en) * 1985-01-16 1986-05-27 Roussel Uclaf 2-aryl pyrazolo[4,3-c]cinnolin-3-ones
DE3626221A1 (de) 1986-08-02 1988-02-04 Agfa Gevaert Ag Farbfotografisches aufzeichnungsmaterial zur herstellung farbiger aufsichtsbilder
US4906644A (en) 1986-11-20 1990-03-06 Mitsubishi Kasei Corporation Lipid-peroxide formation inhibiting composition and novel compounds useful therefor
DE3903993A1 (de) * 1989-02-10 1990-08-16 Basf Ag Diarylsubstituierte heterocyclische verbindungen, ihre herstellung und arzneimittel daraus
AR006520A1 (es) 1996-03-20 1999-09-08 Astra Pharma Prod Derivados de 2-arilpirazolisoquinolina y cinolinona y procedimiento para su preparacion.
GB9713707D0 (en) 1997-06-27 1997-09-03 Merck Sharp & Dohme Therapeutic agents
SE0102404D0 (sv) * 2001-07-04 2001-07-04 Active Biotech Ab Novel immunomodulating compounds
WO2003004485A1 (en) 2001-07-05 2003-01-16 Takeda Chemical Industries, Ltd. Benzo-fused 5-membered hetrocycle compounds, process for preparation of the same, and use thereof
US7566711B2 (en) * 2001-10-12 2009-07-28 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
EP1562944B1 (en) 2002-11-22 2007-02-14 Active Biotech AB Pyrazoloquinolines with immunomodulating activity
ATE425164T1 (de) 2002-12-16 2009-03-15 Active Biotech Ab Tetrazyklische immunmodulierende verbindungen
EP2284172A1 (en) * 2003-03-14 2011-02-16 MediGene Ltd. Immunomodulating heterocyclic compounds
GB0325644D0 (en) * 2003-11-04 2003-12-10 Avidex Ltd Immuno ihibitory pyrazolone compounds
GB0411770D0 (en) * 2004-05-26 2004-06-30 Avidex Ltd Immuno inhibitory heterocyclic compouds
DK1776366T3 (da) * 2004-08-09 2009-02-16 Medigene Ltd Immunomodulerende oxopyrazolocinnoliner som CD80-inhibitorer
US20060221590A1 (en) * 2005-03-31 2006-10-05 Edoardo Campini System and method for Advanced Mezzanine Card connection
GB0603522D0 (en) * 2006-02-22 2006-04-05 Avidex Ltd Kinase inhibition

Also Published As

Publication number Publication date
WO2004081011A1 (en) 2004-09-23
EA009680B1 (ru) 2008-02-28
BRPI0408365B1 (pt) 2018-11-21
PT1603917E (pt) 2011-02-04
KR20050121681A (ko) 2005-12-27
PL1603917T3 (pl) 2011-12-30
DK1603917T3 (da) 2011-02-28
PL383655A1 (pl) 2008-04-14
EP2284172A1 (en) 2011-02-16
EA200501370A1 (ru) 2006-08-25
US7276505B2 (en) 2007-10-02
NZ541973A (en) 2009-06-26
DE602004030225D1 (de) 2011-01-05
CA2519063A1 (en) 2004-09-23
SI1603917T1 (sl) 2011-04-29
EP1603917A1 (en) 2005-12-14
CA2519063C (en) 2011-05-10
JP4892338B2 (ja) 2012-03-07
NO20054710L (no) 2005-12-13
BRPI0408365A (pt) 2006-03-21
JP2006520372A (ja) 2006-09-07
IL170389A (en) 2013-08-29
AU2004220310A1 (en) 2004-09-23
MXPA05009667A (es) 2006-01-27
KR101133959B1 (ko) 2012-04-09
US8309552B2 (en) 2012-11-13
ATE489388T1 (de) 2010-12-15
EA014080B1 (ru) 2010-08-30
EP1603917B1 (en) 2010-11-24
NO20054710D0 (no) 2005-10-13
US20080045527A1 (en) 2008-02-21
EA200702435A1 (ru) 2008-06-30
BRPI0408365B8 (pt) 2021-05-25
US20090312334A1 (en) 2009-12-17
HK1090921A1 (en) 2007-01-05
US7598247B2 (en) 2009-10-06
US20070021428A1 (en) 2007-01-25
NO332136B1 (no) 2012-07-02

Similar Documents

Publication Publication Date Title
ECSP056104A (es) Compuestos heterociclicos inmunomoduladores
NL300927I9 (nl) Tivozanib of een zout, solvaat of hydraat ervan, in het bijzonder het hydrochloride-monohydraat
GB0214149D0 (en) Chemical compounds
GB2392154B (en) Protein Kinase Inhibitors
GB2398781B (en) Kinase inhibitors
PT1585739E (pt) Arilciclopropilacetamidas substitu?das como activadores da glucocinase
AU2003229953A8 (en) Phthalazinone derivatives
NO20054669L (no) Substituerte kinobenzoxazinanaloger
DE60319080D1 (de) Phenyloxyalkansäure-derivate als hppar aktivatore
HK1086835A1 (en) N-[({'4-substituted piperazine-1-y}sulfonylmethyl)alkyl]-n-hxdroxyformamide compounds as metallopro teinase inhibitors
GB0215392D0 (en) Chemical compounds
DE602004031878D1 (de) Immunhemmende pyrazolon-verbindungen
TW200518748A (en) Chemical compounds
WO2004103305A3 (en) Spiropyrazole compound